Published in Epidemiology on March 01, 2016
Estimation of HIV incidence in the United States. JAMA (2008) 21.27
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Approximate Bayesian computation in population genetics. Genetics (2002) 13.06
HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. Lancet Infect Dis (2013) 3.10
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect (2012) 2.88
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
Measuring the HIV/AIDS epidemic: approaches and challenges. Epidemiol Rev (2010) 2.53
Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med (2008) 2.26
Mathematical models in the evaluation of health programmes. Lancet (2011) 2.05
National estimate of HIV prevalence in the Netherlands: comparison and applicability of different estimation tools. AIDS (2011) 1.65
Approximate Bayesian computation. PLoS Comput Biol (2013) 1.60
27 years of the HIV epidemic amongst men having sex with men in the Netherlands: an in depth mathematical model-based analysis. Epidemics (2010) 1.26
HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. AIDS (2011) 1.26
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med (2010) 1.23
Bayesian evidence synthesis for a transmission dynamic model for HIV among men who have sex with men. Biostatistics (2011) 1.13
HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med (2007) 1.11
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med (2008) 1.09
A multistate approach for estimating the incidence of human immunodeficiency virus by using HIV and AIDS French surveillance data. Stat Med (2009) 1.03
HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation. PLoS Med (2012) 0.99
Projected demographic profile of people living with HIV in Australia: planning for an older generation. PLoS One (2012) 0.94
Routine surveillance data on AIDS and HIV infections in the UK: a description of the data available and their use for short-term planning. Epidemiol Infect (1988) 0.88
AIDS case reporting: do we still need it? Lancet (2008) 0.85
Introduction to recent developments in HIV epidemic modeling. Curr Opin HIV AIDS (2011) 0.84
Back-calculation and projection of the HIV/AIDS epidemic among homosexual/ bisexual men in three European countries: evalution of past projections and updates allowing for treatment effects. Eur J Epidemiol (2004) 0.83
The HIV cascade of care in Georgia: implications for countries in Eastern Europe and Central Asia (EECA). HIV Med (2015) 0.78
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet (2014) 6.69
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Addressing the "risk environment" for injection drug users: the mysterious case of the missing cop. Milbank Q (2004) 3.72
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol (2007) 3.69
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ (2008) 3.56
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
The temporal pattern of mortality responses to air pollution: a multicity assessment of mortality displacement. Epidemiology (2002) 3.21
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Acute effects of ozone on mortality from the "air pollution and health: a European approach" project. Am J Respir Crit Care Med (2004) 2.89
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS (2014) 2.67
The gibberellin pathway mediates KNOTTED1-type homeobox function in plants with different body plans. Curr Biol (2002) 2.61
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis (2013) 2.60
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
KNOX action in Arabidopsis is mediated by coordinate regulation of cytokinin and gibberellin activities. Curr Biol (2005) 2.54
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Air pollution and health: a European and North American approach (APHENA). Res Rep Health Eff Inst (2009) 2.33
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Estimating the exposure-response relationships between particulate matter and mortality within the APHEA multicity project. Environ Health Perspect (2005) 2.25
A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol (2003) 2.23
The temporal pattern of respiratory and heart disease mortality in response to air pollution. Environ Health Perspect (2003) 2.22
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med (2011) 2.17
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS (2008) 2.14
Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis (2011) 2.11
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials (2010) 2.10
Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One (2010) 2.04
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Acute effects of ambient particulate matter on mortality in Europe and North America: results from the APHENA study. Environ Health Perspect (2008) 1.93
Inference for nonlinear epidemiological models using genealogies and time series. PLoS Comput Biol (2011) 1.91
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis (2007) 1.88
Bivariate linear mixed models using SAS proc MIXED. Comput Methods Programs Biomed (2002) 1.87
Estimating the basic reproductive number from viral sequence data. Mol Biol Evol (2011) 1.86
Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. Curr HIV Res (2007) 1.85
Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. Epidemiology (2015) 1.83
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76